C4 Therapeutics

CCCCNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$412.416 M

$3.73 +2.47%

Close of 7 Aug 2026

Revenue

$35.9M

#2842 by revenue

Earnings

-$105.0M

Loss-making

Shares outstanding

110,567,222

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#76Scribe TherapeuticsSCTX$420.7M
#77Sutro BiopharmaSTRO$420.6M
#78C4 TherapeuticsCCCC$412.4M
#79Fennec PharmaceuticalsFENC$403.8M
#80Compass TherapeuticsCMPX$387.2M

Where these numbers come from

Share counts and financials for C4 Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.